2014 Genitourinary Cancers Symposium

Dr Vincent Launay-Vacher from Pitie-Salpetriere Hospital, Paris, France talks to ecancertv at ASCO GU congress 2014 about the results of the MARS study. This study is assessing the renovascular tolerance of anti-VEGF drugs in a clinical setting. Dr Launay-Vacher also discusses the new Cancer & the Kidney International Network C-KIN

This expert panel discussion took place at ASCO GU 2014. Dr Karim Fizazi (Institut Gustave Roussy, Paris, France) chairs the discussion between Dr Peter Nelson (Fred Hutchinson Cancer Research Center, Seattle, USA), Dr Cora Sternberg (San Camillo-Forlanini Hospital, Rome, Italy), Dr John Fitzpatrick (Irish Cancer Society, Dublin, Ireland) and Dr Heather Payne (University College Hospital, London, United Kingdom). The panel discuss the changing landscape of prostate cancer over the last decade and how this has impacted on treatment practices and outcomes for patients. They cover: Abstract LBA1: Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of the phase III PREVAIL study. 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III ALSYMPCA study. Results from a phase III, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial). And further discuss: - The potential future of the evolving treatment options in CRPC - Clinical strategies to overcome androgen resistance - Treatment options are available for patients with CRPC - The correct sequence for the use of newly available drugs for the management of CRPC - Patient sub-groups that can optimally benefit from new treatment approaches This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Dr Maria De Santis from the Kaiser Franz Josef Hospital, Vienna, Austria talks to ecancertv at ASCO GU congress 2014 about the state of play for CPRC treatment and what the future might hold. She covers results announced at ASCO GU such as the phase III PREVAIL trial looking at enzalutamide and answers questions submitted by ecancer members. The video looks at: - Potential clinical strategies to overcome androgen resistance - What treatment options are available for patients with CRPC - Sequencing for the use of newly available drugs for the management of CRPC This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Dr Karim Fizazi of Institut Gustave Roussy in Paris, France at the ASCO GU congress 2014 explores the results of phase III trials looking at whether or not Gleason scores predict efficacy of abiraterone acetate therapy in patients with mCRPC. The discussion includes the potential future of treatment options in CRPC, clinical strategies overcoming androgen resistance, treatment options available to patients with CRPC, correct sequencing for the use of newly available drug for CRPC management and identification of patient sub-groups that may optimally benefit from novel treatment approaches. This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

At an expert to expert discussion at the ASCO GU congress 2014, Dr Chris Parker from The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom is joined by Dr Kurt Miller from the Benjamin Franklin Medical Center, Berlin, Germany to examine the use of enzalutamide and abiraterone acetate in men with mCRPC and asks what the future may look like for prostate cancer patients. The discussion includes: - Clinical strategies to overcome androgen resistance - What treatment options are available for patients with CRPC - Determining the correct sequence for the use of newly available drugs for the management of CRPC and issues with cross resistance - Identification of patient sub-groups that can optimally benefit from new treatment approaches using predictive markers - Future predictions on treatment based on the results of the PREVAIL trial - Where Ra-223 fits into the treatment landscape This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Dr Ari Hakimi of the Memorial Sloan-Kettering Cancer Center, New York, USA, at the ASCO GU congress 2014 discusses the MET variant as a prognostic marker in clear cell renal cell carcinoma (ccRCC) and its future implications.

Dr Rafael Sanchez-Salas talks to ecancer at the ASCO GU 2014 cancer congress. Several indicators of intermittent androgen deprivation (IAD) outcomes in prostate cancer have been interpreted as potentially predictive, including prostate-specific antigen (PSA) nadir following first on-treatment period, off-phase interval duration and PSA doubling time. Improvement of the forecast of clinical outcomes is expected through identification and analysis of the different types of off-treatment period.

Dr Sten Nilsson from Karolinska University Hospital, Stockholm, Sweden joins ecancer at ASCO GU 2014 to discuss recent data from the phase III ALSYMPCA trial. The discussion includes how radium-223 is an effective treatment against mCRPC and bone metastases.

At an expert to expert discussion at ASCO GU congress 2014, Dr Chris Parker from The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom is joined by Professor Stephane Oudard from Georges Pompidou Hospital, Paris, France to discuss the latest clinical strategies used to treat metastatic castration-resistant prostate cancer (mCRPC). They cover: - The impact of prior endocrine therapy on radiographic progression-free survival in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: results from COU-AA-302 - The response to androgen signaling-directed therapy after treatment with abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post-hoc analysis of study - The association of alkaline phosphatase with clinical outcomes in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: results from COU-AA-302 - Data from the PREVAIL trial The discussion looks at the potential future of the evolving treatment options in CRPC in terms of: - Understanding clinical strategies to overcome androgen resistance - Understanding what treatment options are available for patients with CRPC - Determining the correct sequence for the use of newly available drugs for the management of CRPC - Identifying patient sub-groups that can optimally benefit from new treatment approaches This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Dr Robert Dreicer from the Cleveland Clinic, Cleveland, USA, talks to ecancertv at the ASCO GU congress 2014 about the phase III TAK-700 trial testing orteronel plus prednisone in patients with mCRPC. The study showed that orteronel has clinically meaningful activity, with significant improvements in radiographical progression-free survival, but not overall survival.

Dr Nelson talks to ecancertv at ASCO GU 2014. Targeting the androgen receptor pathway to tackle prostate cancer has been a staple of treatment for decades; Dr Nelson looks at the biological basis behind this, with a view to new and future agents.

Dr Tomasz M. Beer from Oregon Health & Science University, Portland, USA, speaks to ecancer at the ASCO GU congress 2014. He discusses the results from the phase III PREVAIL trial showing increased survival and delayed progression of mCRPC in men. Data were presented in full for the first time at the GU Cancer symposium. Dr Beer states that the androgen-receptor blocker enzalutamide is likely to become an important new treatment option if approved.